It is very noble of you Mr. Pharma to update us on what is available in the Chinese market. We were hoping that these updates will influence the SP positively. Unfortunately there has been zero interest in the company. I am sure the revenues in China will be very high according to your posting and a few others. An update from the management on Chinese revenues will therefore be needed to support this. It has been over a year now since the Chinese venture and absolutely no news on revenues. Or is it just another of the many Cellmid dissapointments.
On another note, I support a change on company name but this will have zero impact on SP if the management remain the same. After all this will be the second or third name change and SP kept on going down.
- Forums
- ASX - By Stock
- AN1
- Ann: Cellmid receives R&D tax credit
Ann: Cellmid receives R&D tax credit, page-6
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable